Invivyd Announces Landmark Developments in COVID-19 and Measles Antibody Pipeline – Key Updates for Investors

Key Highlights from Invivyd’s Latest Corporate Update

• Significant progress in the pivotal Phase 3 DECLARATION study of VYD2311 for COVID-19 prevention, with robust event accrual and a strategic increase in sample size.
• Study expansion triggers about 500 additional subjects, likely shifting top-line results from “mid-year” to Q3 2026.
• Regulatory alignment with the U.S. FDA on a Pediatric Study Plan for VYD2311, paving the way for the “DRUMMER” pediatric trial—pending adult trial success.
• Breakthrough in measles: Discovery and advancement of VMS063, a novel, highly potent, broadly neutralizing, half-life-extended monoclonal antibody targeting measles, moving rapidly toward IND-enabling studies with target IND readiness by late 2026.
• Management scheduled a conference call on April 9th to discuss these updates.

Detailed Program Updates

1. DECLARATION Phase 3 Study of VYD2311 for COVID-19

The DECLARATION study is Invivyd’s pivotal Biologics License Application (BLA)-directed Phase 3 trial evaluating the safety and efficacy of VYD2311—a novel monoclonal antibody—for pre-exposure prophylaxis of COVID-19. The trial employs a conservative, algorithmic sample size re-estimation to ensure adequate statistical power, given potential variability in COVID-19 community attack rates.

• As of April 6th, with 1,500 out of 1,818 enrolled patients reaching Day 45 of 90, the pooled, blinded event data already support strong statistical power for high-end efficacy projections.
• The sample size re-estimation triggered the addition of ~500 subjects, expected to shift the anticipated readout from “mid-year” to Q3 2026. This expansion, combined with accrued events, increases confidence in the study’s outcome and supports a broader range of efficacy scenarios.
• These developments are significant as they:
  • Enhance the robustness and potential regulatory acceptance of the dataset.
  • May impact the competitive landscape for COVID-19 prophylaxis, especially in immunocompromised populations.

2. Regulatory Progress on Pediatric Indication

Invivyd and the U.S. FDA have aligned on an Initial Pediatric Study Plan for VYD2311, setting the stage for a BLA-directed pivotal pediatric immunobridging and safety trial (the “DRUMMER” study) in children aged 0-11 years. This study will proceed only if the DECLARATION trial is successful, offering Invivyd a rapid pathway to expand VYD2311’s potential market into the pediatric population.

3. Breakthrough Measles Antibody Candidate: VMS063

In a potentially transformative move, Invivyd has announced the discovery and advancement of VMS063, a novel monoclonal antibody candidate for the treatment and prevention of measles. VMS063 is engineered to be highly potent, broadly neutralizing, and has an extended half-life for optimal prophylactic and therapeutic use.

• VMS063 targets the conserved measles Fusion (F) protein, locking it in a pre-fusion state—preventing viral cell entry. This approach is akin to successful RSV therapies and positions VMS063 as a potential first- and best-in-class precision therapy for measles.
• The antibody demonstrates high potency in both pseudovirus (high pg/mL IC50s) and authentic virus assays (low ng/mL IC50s) across major measles lineages, including currently circulating B3 and D8 strains, and the ancestral Edmonston strain.
• The targeted epitope is conserved across all described measles variants spanning the last 50 years, supporting broad utility.
• IND-enabling and manufacturing activities are underway, with regulatory outreach aiming for IND submission readiness by late 2026.
• The U.S. is experiencing a surge in measles cases, with outbreaks in over thirty states and the first domestic deaths in a decade. Declining vaccination rates have created an “immunity gap” affecting millions of children and immunocompromised adults, further heightening the need for new therapeutic options.
• VMS063 is envisioned for three major use cases:
  1. Treatment of symptomatic measles, to reduce duration and severe complications.
  2. Pre- and post-exposure prophylaxis to control outbreaks and offer alternatives for vaccine-hesitant or ineligible individuals.
  3. Early childhood passive prophylaxis (similar to RSV), bridging infants to safe vaccination and potentially improving early neurodevelopmental outcomes by allowing delayed vaccination.

4. Strategic Vision and Pipeline Expansion

Invivyd’s Chairman, Marc Elia, emphasized the company’s goal to reshape infectious disease management. By building a platform capable of rapid antibody generation for multiple pathogens—including COVID-19, measles, and RSV—Invivyd aims to deliver high-impact medicines with immediate utility, potentially shifting the paradigm for prevention (e.g., making mRNA COVID vaccine boosters a second-line option).

The company also hinted at further pipeline expansion targeting additional pathogens, with further announcements expected later in 2026.

Shareholder Considerations and Potential Price-Sensitive Information

• Positive: The DECLARATION study’s interim success and sample size expansion may reinforce investor confidence in eventual approval and commercial prospects for VYD2311.
• Regulatory progress with the FDA, especially the pediatric pathway, opens new market segments and accelerates time-to-market for broader populations.
• VMS063’s advancement could position Invivyd as the first to market with a precision monoclonal antibody for measles—addressing urgent unmet medical needs amid a national resurgence and declining vaccination rates.
• Tangible catalysts: Upcoming clinical readouts (now expected Q3 2026 for DECLARATION), IND submission for VMS063 by late 2026, and further pipeline disclosures could drive share price movement.
• Risks: As with all biotech companies, progress is subject to clinical, regulatory, and market uncertainties. The company’s forward-looking statements highlight risks including clinical trial outcomes, regulatory hurdles, manufacturing challenges, and funding needs.

About Invivyd

Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company focused on delivering antibody-based protection against serious viral infectious diseases, beginning with SARS-CoV-2. The company leverages a proprietary antibody engineering platform with the goal of rapid, high-value medicine generation for emerging and re-emerging threats.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. All forward-looking statements are subject to risks and uncertainties as outlined by the company’s disclosures and SEC filings. Investors should conduct their own due diligence and consult with professional advisers before making any investment decisions.

View Invivyd, Inc. Historical chart here